TNGX - Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Benzinga
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that one abstract has been selected for an oral minisymposium and seven abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
Abstract accepted for oral minisymposium
Title: TNG260, a small molecule CoREST inhibitor, sensitizes STK11-mutant NSCLC to anti-PD1 immunotherapy
Abstract #: 3916
Session Title: Immune Targets and Therapies
Presenter: Ayushi Patel, Ph.D., NYU Langone Health
Date and Time: Monday April 8, 2024, 2:30 – 4:30 p.m. PT
Abstracts accepted for poster presentation
Title: Genome-wide drug anchor screens identify CAAP1 and AKAP17A as regulators of PRMT5 inhibitor sensitivity
Abstract #: 4636
Presenter: Satoshi Yoda, M.D., Ph.D., Principal Scientist, Tango Therapeutics
Date and Time: April 9, 2024, 9:00 a.m. – 12:30 p.m. PT
Title: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors
Abstract #: 4631
Presenter: Kimberly Briggs, Ph.D., Director, Tango Therapeutics
Date and Time: April 9, 2024, 9:00 a.m. – 12:30 p.m. PT
Title: TNG348 is synergistic with PARP inhibitors in tumor models with elevated replication stress
Abstract #: 4527
Presenter: Antoine Simoneau, Ph.D., Senior Scientist, Tango Therapeutics
Date and Time: April 9, 2024, 9:00 a.m. – 12:30 p.m. PT
Title: TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumors
Abstract #: 3242
Presenter: Yingnan Chen, Ph.D., Senior Director, Tango Therapeutics
Date and Time: April 8, 2024, 1:30 – 5:00 p.m. PT
Title: Experimental ‘loss-of function' annotation of STK11 mutations with prognostic and therapeutic implications
Abstract #: 5584
Presenters: Silvia Fenoglio, Ph.D., Principal Scientist, Tango Therapeutics and Brian Haines, Ph.D., Vice President, Tango Therapeutics
Date and Time: April 9, 2024, 1:30 – 5:00 p.m. PT
Title: LIG1 inactivation selectively inhibits growth of BRCA1 mutant cells in vitro and in vivo
Abstract #: 3363
Presenter: Hilary Nicholson, Ph.D., Principal Scientist, Tango Therapeutics
Date and Time: April 8, 2024, 1:30 – 5:00 p.m. PT
Title: Stearoyl-CoA desaturase is a synthetic lethal target in SMAD4-deficient cancers
Abstract #: 558
Presenter: Alvin Lu, Ph.D., Principal Scientist, Tango Therapeutics
Date and Time: April 7, 2024, 1:30 – 5:00 p.m. PT
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next ...